{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T02:16:56Z","timestamp":1774059416157,"version":"3.50.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>Angiopoietin-like 3 protein (ANGPTL3) is an inhibitor of both lipoprotein lipase and endothelial lipase in humans. Population studies indicate a relationship between loss of function mutations in ANGPTL3 and favorable reductions in triglycerides and non- high-density lipoprotein cholesterol. In addition, loss of function mutations is associated with a reduced risk of coronary artery disease. Whereas ANGPTL3\u2019s role in human lipid metabolism has yet to be fully clarified, it is unlikely that ANGPTL3 impacts cholesterol uptake via the low-density lipoprotein-receptor, unlike the proprotein convertase subtilisin\/kexin9 inhibitors. In contrast to other forms of lipid-lowering therapy, ANGPTL3 inhibition may improve insulin sensitivity. The promise of this new therapy, particularly its independence from the low-density lipoprotein-receptor, has prompted the creation of a monoclonal antibody inhibitor; evinacumab. Evinacumab has shown favorable lipid-lowering action in both human and mouse models. Efficacy trials are currently ongoing and will be completed in the near future. In addition, ANGPTL3 inhibition via an antisense oligonucleotide was performed in healthy human subjects, which resulted in a dose-dependent reduction in circulating ANGPTL3 levels and an antiatherogenic lipid profile. When tested in mouse models, administration of the antisense oligonucleotide caused a reduction in progression of atherosclerosis. Further investigation is required to evaluate the efficacy, safety and net benefit of clinical ANGPTL3 inhibition before it can be accepted into clinical practice.<\/jats:p>","DOI":"10.1097\/crd.0000000000000258","type":"journal-article","created":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T01:43:29Z","timestamp":1555724609000},"page":"211-217","source":"Crossref","is-referenced-by-count":26,"title":["Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment"],"prefix":"10.1097","volume":"27","author":[{"given":"William","family":"Lang","sequence":"first","affiliation":[{"name":"Department of Medicine, Rhode Island Hospital, Brown University, Providence, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230903","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease.","volume":"1","author":"Taylor","year":"2013","journal-title":"Cochrane Database of Syst Rev"},{"key":"R2-20230903","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"25 pt B","key":"R3-20230903","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"81","DOI":"10.18433\/J36C8N","article-title":"Does evolocumab, as a PCSK9 inhibitor, ameliorate the lipid profile in familial hypercholesterolemia patients? A meta-analysis of randomized controlled trials.","volume":"20","author":"Eslami","year":"2017","journal-title":"J Pharm Pharm Sci"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial.","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jacc.2013.09.048","article-title":"AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).","volume":"63","author":"Desai","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","article-title":"2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk.","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","article-title":"2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"suppl 2","key":"R11-20230903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease.","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","article-title":"Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial.","volume":"2","author":"Arrieta","year":"2017","journal-title":"JAMA Cardiol"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.jacc.2017.10.001","article-title":"PCSK9 inhibitors: economics and policy.","volume":"70","author":"Hlatky","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ng814","article-title":"Angptl3 regulates lipid metabolism in mice.","volume":"30","author":"Koishi","year":"2002","journal-title":"Nat Genet"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJM198904203201607","article-title":"Lipoprotein lipase.","volume":"320","author":"Eckel","year":"1989","journal-title":"N Engl J Med"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1056\/NEJMe1706907","article-title":"Increasing lipolysis and reducing atherosclerosis.","volume":"377","author":"Tall","year":"2017","journal-title":"N Engl J Med"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","article-title":"Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase.","volume":"27","author":"Shimamura","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cmet.2007.07.009","article-title":"Hepatic proprotein convertases modulate HDL metabolism.","volume":"6","author":"Jin","year":"2007","journal-title":"Cell Metab"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia.","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1096-8628(19980226)76:1<79::AID-AJMG15>3.0.CO;2-M","article-title":"Genetic heterogeneity in familial hypobetalipoproteinemia: linkage and non-linkage to the apoB gene in Caucasian families.","volume":"76","author":"Pulai","year":"1998","journal-title":"Am J Med Genet"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease.","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-1298","article-title":"Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization.","volume":"97","author":"Minicocci","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","article-title":"Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion.","volume":"56","author":"Wang","year":"2015","journal-title":"J Lipid Res"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1194\/jlr.M300031-JLR200","article-title":"A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice.","volume":"44","author":"Ando","year":"2003","journal-title":"J Lipid Res"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"13735","DOI":"10.1074\/jbc.M807899200","article-title":"Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL).","volume":"284","author":"Lee","year":"2009","journal-title":"J Biol Chem"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/ATVBAHA.113.301397","article-title":"Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids.","volume":"33","author":"Robciuc","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0006-291X(02)03058-9","article-title":"Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes.","volume":"301","author":"Shimamura","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/MCO.0b013e328042ba90","article-title":"Free fatty acids and insulin resistance.","volume":"10","author":"Delarue","year":"2007","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2337\/dc09-0738","article-title":"Statin therapy and risk of developing type 2 diabetes: a meta-analysis.","volume":"32","author":"Rajpathak","year":"2009","journal-title":"Diabetes Care"},{"key":"R33-20230903","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/01.ATV.15.9.1512","article-title":"A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.","volume":"15","author":"Stary","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides.","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"},{"key":"R39-20230903","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.jacc.2017.03.015","article-title":"Editorial comment: ANGPTL3: a gene, a protein, a new target? aye, there\u2019s the rub!","volume":"69","author":"Genest","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R40-20230903","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease.","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R41-20230903","doi-asserted-by":"crossref","first-page":"17281","DOI":"10.1074\/jbc.M109768200","article-title":"ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo.","volume":"277","author":"Camenisch","year":"2002","journal-title":"J Biol Chem"},{"key":"R42-20230903","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.jacc.2017.06.076","article-title":"Concerns on the genetic or therapeutic antagonism of ANGPTL3.","volume":"70","author":"Luo","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R43-20230903","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.jacc.2017.07.794","article-title":"Reply: loss-of-function mutations to estimate pharmacological ANGPTL3 inhibition.","volume":"70","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R44-20230903","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R45-20230903","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur Heart J"},{"key":"R46-20230903","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2016.02.011","article-title":"Role of PCSK9 antibodies in cardiovascular disease: critical considerations of mortality and neurocognitive findings from the current literature.","volume":"247","author":"Ko\u0142odziejczak","year":"2016","journal-title":"Atherosclerosis"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00045415-201907000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:28:29Z","timestamp":1693733309000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201907000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000258","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}